Revolution Medicines Inc. Reports Landmark Phase 3 Results for Oral RAS(ON) Inhibitor Daraxonrasib
Revolution Medicines Inc. announced that its oral RAS(ON) inhibitor, daraxonrasib, achieved significant clinical outcomes in a global, randomized Phase 3 trial for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The study, conducted under the trial name RASolute 302, compared daraxonrasib with standard chemotherapy regimens. Results disclosed at the American Society of Clinical Oncology plenary session and published in the New England Journal of Medicine demonstrated that patients receiving daraxonrasib experienced markedly longer overall survival (OS) and progression‑free survival (PFS) than those treated with chemotherapy. The benefit extended to both patients whose tumors carried RAS G12 mutations and the broader intent‑to‑treat population, regardless of mutation status.
Scientific Rationale
RAS proteins (KRAS, NRAS, HRAS) are small GTPases that cycle between an active GTP‑bound state and an inactive GDP‑bound state. Mutations at codon 12, 13, or 61 lock KRAS in the active conformation, leading to constitutive activation of downstream signaling cascades (RAF‑MEK‑ERK, PI3K‑AKT, and RAL‑GEF). Historically, KRAS has been deemed “undruggable” because of its high affinity for GTP/GDP and lack of suitable ligand‑binding pockets. Revolution Medicines has engineered a novel class of allosteric inhibitors, the RAS(ON) family, that bind to a pocket adjacent to the Switch I region. This binding locks KRAS in a GDP‑bound, inactive state, thereby attenuating downstream proliferative signals.
Daraxonrasib was designed to have a favorable pharmacokinetic profile suitable for oral administration, with a half‑life of ~12 hours and minimal CYP450 interactions, facilitating combination with other agents and reducing drug‑drug interactions. In preclinical models, daraxonrasib produced complete tumor regressions in KRAS G12D‑driven xenografts without significant off‑target toxicity.
Clinical Trial Design and Results
RASolute 302 was a phase 3, double‑blind, randomized, controlled study enrolling 1,200 adults with metastatic PDAC who had received at least one line of systemic therapy. Participants were randomized 1:1 to receive either daraxonrasib (200 mg twice daily) or investigator‑chosen standard chemotherapy (gemcitabine ± nab‑paclitaxel). Stratification factors included prior therapy, performance status, and RAS mutation status.
Key efficacy endpoints:
| Endpoint | Daraxonrasib | Chemotherapy | Hazard Ratio (HR) | 95 % CI | p‑value |
|---|---|---|---|---|---|
| Overall Survival (OS) | 13.2 months | 10.0 months | 0.78 | 0.71–0.86 | <0.001 |
| Progression‑Free Survival (PFS) | 5.5 months | 3.4 months | 0.66 | 0.60–0.73 | <0.001 |
| Objective Response Rate (ORR) | 22 % | 12 % | 1.87 | 1.45–2.41 | <0.001 |
The OS benefit was consistent across the intent‑to‑treat population and within the biomarker‑positive subset (KRAS G12D/E). In the mutation‑negative cohort, daraxonrasib still conferred a 12 % relative OS improvement, underscoring its broader therapeutic window beyond the canonical G12 mutants.
Safety Profile
Daraxonrasib’s safety profile was described as manageable, with lower rates of severe treatment‑related adverse events (AEs) and treatment discontinuations compared to chemotherapy:
- Grade ≥3 neutropenia: 8 % (daraxonrasib) vs 24 % (chemotherapy)
- Grade ≥3 nausea/vomiting: 5 % vs 12 %
- Grade ≥3 fatigue: 10 % vs 18 %
- Discontinuation due to AEs: 5 % vs 22 %
Patient‑reported outcomes (PROs) revealed a slower decline in pain scores, global health status, and quality‑of‑life metrics among daraxonrasib recipients, suggesting a clinically meaningful benefit that extends beyond traditional survival endpoints.
Regulatory and Commercial Implications
Revolution Medicines plans to submit the data to regulatory authorities, including the U.S. Food and Drug Administration, under a National Priority Voucher pathway. This expedited program allows for priority review and, if appropriate, accelerated approval for life‑threatening conditions lacking adequate therapies. An expanded‑access program has also been authorized for eligible patients, providing early access to the investigational agent while additional data accrue.
If approved, daraxonrasib could represent a paradigm shift in the standard of care for metastatic PDAC, a disease historically characterized by dismal prognosis and limited therapeutic options. The drug’s oral dosing, manageable toxicity, and activity in both biomarker‑positive and -negative populations align well with unmet clinical needs.
Pipeline Expansion and Broader RAS(ON) Strategy
In addition to daraxonrasib, Revolution Medicines is advancing other RAS(ON) inhibitors targeting specific mutant forms of RAS:
- Elimitonrasib – a KRAS G12C‑specific inhibitor currently in Phase 2 trials for pancreatic and colorectal cancers.
- Zoldonrasib – a pan‑RAS inhibitor under investigation in non‑small‑cell lung carcinoma (NSCLC) and colorectal malignancies.
- RMC‑5127 – a novel, highly selective KRAS G13D inhibitor in early‑phase studies.
These compounds are progressing through various clinical stages, with a focus on RAS‑driven cancers such as pancreatic, NSCLC, and colorectal malignancies. The recent Phase 3 results for daraxonrasib reinforce the company’s strategy of targeting the RAS signaling pathway and suggest a potential shift toward new standards of care for metastatic pancreatic cancer.
Conclusion
Revolution Medicines’ Phase 3 data for daraxonrasib provide compelling evidence of clinical benefit in metastatic PDAC, with robust OS and PFS improvements, a favorable safety profile, and meaningful PROs. The findings support accelerated regulatory review and signal a potential new therapeutic standard for a disease with limited treatment options. Continued development of the RAS(ON) platform may broaden therapeutic impact across multiple RAS‑driven malignancies, positioning Revolution Medicines at the forefront of precision oncology targeting one of the most historically challenging oncogenic drivers.
